DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Maximilian Winter - 1 doggedly - 1 Lyme - 1 Fritz Winter - 1 Peter Thiel - 1 There's - 1 Peter Fioretti - 1 David Sinclair - 1
Top related locs:
Santa Barbara Quinta , California Maximon Switzerland Zurich
Top related orgs:
Longevity Tech Fund - 1 Harmonix - 1 Biotech - 1 UBS - 1 Winter's Harmonix Fund - 1 Blue - 1 Foods - 1 Becker Venture Partners - 1

Search resuls for: "Newpath Partners"


4 mentions found


☆ Frustrated by healthcare's failings, the rich are investing in biotech to live longer and healthier
  + stars: | 2024-01-30 | by ( Hayley Cuccinello | ) www.businessinsider.com   time to read: +8 min
AdvertisementWinter is part of a growing group of family office principals, including heirs like himself and first-generation entrepreneurs, who are making direct investments in pursuit of longer and healthier lives. They are in good company; longevity startups drew global investment of more than $5.2 billion in 2022 , according to a venture capital firm, Longevity Tech Fund, which used PitchBook data. She and some of her clients are investors in Maximon, a Switzerland-based longevity fund that includes "healthspan clinics" in its portfolio. Eric Becker, cofounder of wealth manager Cresset , and his two sons founded a family office and picked Blue Zone Foods as its first investment. Courtesy of CressetFor Becker, whose daughter died of leukemia at 21, and his family, longevity is not an abstract topic.
Persons: Maximilian Winter, doggedly, Lyme, Fritz Winter, Peter Thiel, There's, Peter Fioretti, David Sinclair, Kathrin Genovese, ultrarich, Genovese, Eric Becker, Cresset, Dan Yadegar, Becker, Johnny Walker Organizations: Longevity Tech Fund, Harmonix, Biotech, UBS, Winter's Harmonix Fund, Blue, Foods, Becker Venture Partners, Newpath Partners Locations: Santa Barbara, Quinta , California, Maximon, Switzerland, Zurich
☆ Biotech firm Prime Medicine valued at $1.8 bln in strong debut
  + stars: | 2022-10-20 | by ( ) www.reuters.com   time to read: +2 min
Oct 20 (Reuters) - Biotechnology firm Prime Medicine (PRME.O) notched a valuation of about $1.8 billion in its Nasdaq debut on Thursday, braving tough market conditions that have forced several IPO-bound companies to slam the breaks on their listing plans. Shares of Prime Medicine started trading nearly 12% above their IPO price of $17 each. Its investors include Alphabet Inc's (GOOGL.O) GV, Newpath Partners, Moore Strategic Ventures and Samsara Biocapital, the firm's website showed. Prime Medicine sold 10.3 million shares in its upsized offering, raising $175 million in proceeds priced at $17 apiece, the midpoint of its proposed range of $16 and $18 per share. Register now for FREE unlimited access to Reuters.com RegisterReporting by Manya Saini in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.
☆ Prime Medicine dipped 10% in its public debut. We dug through the biotech's 283-page filing to find 5 key takeaways about the company's plan to commercialize gene editing.
  + stars: | 2022-10-20 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +8 min
The gene-editing biotech Prime Medicine went public on Thursday. From a key patent to an uncertain timeline, here are five takeaways from Prime's filing. Its goal is to advance prime editing, a twist on CRISPR gene editing that could allow for a wider range of edits to DNA. Prime editing, another version of next-generation gene editing, works like a word processor, "searching for the correct location and replacing or repairing a wide variety of target DNA," the filing said. Jessica Rinaldi/The Boston Globe via Getty ImagesDavid Liu, a Harvard gene-editing scientist who co-invented base editing and prime editing, is Prime's largest shareholder.
☆ Prime Medicine is gearing up for a $200 million IPO. We dug through the biotech's 282-page filing to find 5 key takeaways about the company's plan to commercialize gene editing.
  + stars: | 2022-09-28 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +8 min
From an uncertain timeline to the clinic to a key patent, here are 5 takeaways from Prime's filing. The company's goal is to advance prime editing, a twist on CRISPR gene editing that could allow for a wider range of edits to DNA. Prime editing is another version of next-generation gene editing. Prime's filing comes in a difficult market for biotechs, but particularly for companies that have yet to start human testing. Jessica Rinaldi/The Boston Globe via Getty ImagesDavid Liu, a Harvard gene-editing scientist who co-invented base editing and prime editing, is currently Prime's largest shareholder.
0 next >>
Total: 4